Ensign Peak Advisors
ALDX icon

Ensign Peak Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Ensign Peak Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-41,318
Closed -$491K – 1825
2021
Q1 		$491K Hold
41,318
– – ﹤0.01% 1595
2020
Q4 		$283K Hold
41,318
– – ﹤0.01% 1683
2020
Q3 		$306K Buy
+41,318
New +$267K ﹤0.01% 1613

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Ensign Peak Advisors's ALDX Position: Q2 2021 in Review

Ensign Peak Advisors sold out of Aldeyra Therapeutics (ALDX) in Q2 2021, closing a stake of 41,318 shares — an estimated $491K sold.

Ensign Peak Advisors first reported a position in ALDX in Q3 2020 and held it in 3 quarters. The position peaked at $491K in Q1 2021. 136 funds tracked by Wall St. Rank hold ALDX as of Q2 2021.

  • Ensign Peak Advisors reported no remaining Aldeyra Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Ensign Peak Advisors sold 41,318 Aldeyra Therapeutics shares in Q2 2021, an estimated $491K.
  • Ensign Peak Advisors first reported a position in Aldeyra Therapeutics in Q3 2020 and held it in 3 quarters.
  • Ensign Peak Advisors's Aldeyra Therapeutics position peaked at $491K in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2021.

Based on Ensign Peak Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.